These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 34655050)

  • 61. Relationship between the blood concentrations of tacrolimus and voriconazole in hematopoietic stem cell transplant recipients
.
    Ota R; Hirata A; Noto K; Yokoyama S; Hosomi K; Takada M; Matsuoka H
    Int J Clin Pharmacol Ther; 2019 Nov; 57(11):561-566. PubMed ID: 31426903
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Cytomegalovirus events in high-risk allogeneic hematopoietic-cell transplantation patients who received letermovir prophylaxis.
    Chen K; Arbona-Haddad E; Cheng MP; McDonnell AM; Gooptu M; Orejas JL; Timblin K; Silverman E; Al-Hamed R; Soiffer RJ; Hammond SP; Marty FM
    Transpl Infect Dis; 2021 Aug; 23(4):e13619. PubMed ID: 33866648
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Predictive Value of C-Reactive Protein and Albumin for Temporal Within-Individual Pharmacokinetic Variability of Voriconazole in Pediatric Patients Undergoing Hematopoietic Cell Transplantation.
    Takahashi T; Jaber MM; Smith AR; Jacobson PA; Fisher J; Kirstein MN
    J Clin Pharmacol; 2022 Jul; 62(7):855-862. PubMed ID: 34970774
    [TBL] [Abstract][Full Text] [Related]  

  • 64. No clinically significant pharmacokinetic interactions between voriconazole and indinavir in healthy volunteers.
    Purkins L; Wood N; Kleinermans D; Love ER
    Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):62-8. PubMed ID: 14616416
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Necessity for a Significant Maintenance Dosage Reduction of Voriconazole in Patients with Severe Liver Cirrhosis (Child-Pugh Class C).
    Yamada T; Imai S; Koshizuka Y; Tazawa Y; Kagami K; Tomiyama N; Sugawara R; Yamagami A; Shimamura T; Iseki K
    Biol Pharm Bull; 2018 Jul; 41(7):1112-1118. PubMed ID: 29760306
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation.
    Marty FM; Ljungman P; Chemaly RF; Maertens J; Dadwal SS; Duarte RF; Haider S; Ullmann AJ; Katayama Y; Brown J; Mullane KM; Boeckh M; Blumberg EA; Einsele H; Snydman DR; Kanda Y; DiNubile MJ; Teal VL; Wan H; Murata Y; Kartsonis NA; Leavitt RY; Badshah C
    N Engl J Med; 2017 Dec; 377(25):2433-2444. PubMed ID: 29211658
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Coadministration of letermovir and sirolimus in allogeneic hematopoietic cell transplant recipients.
    Xue E; Lorentino F; Clerici D; Farina F; Oltolini C; Giglio F; Campodonico E; Nitti R; Bernardi M; Corti C; Peccatori J; Ciceri F; Lupo Stanghellini MT; Greco R
    Bone Marrow Transplant; 2022 Jan; 57(1):128-130. PubMed ID: 34625664
    [No Abstract]   [Full Text] [Related]  

  • 68. Effect of Genetic Polymorphism of CYP3A5 and CYP2C19 and Concomitant Use of Voriconazole on Blood Tacrolimus Concentration in Patients Receiving Hematopoietic Stem Cell Transplantation.
    Iwamoto T; Monma F; Fujieda A; Nakatani K; Gayle AA; Nobori T; Katayama N; Okuda M
    Ther Drug Monit; 2015 Oct; 37(5):581-8. PubMed ID: 25565672
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Letermovir prophylaxis in solid organ transplant-Assessing CMV breakthrough and tacrolimus drug interaction.
    Winstead RJ; Kumar D; Brown A; Yakubu I; Song C; Thacker L; Gupta G
    Transpl Infect Dis; 2021 Aug; 23(4):e13570. PubMed ID: 33469975
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Serial plasma voriconazole concentrations after allogeneic hematopoietic stem cell transplantation.
    Trifilio SM; Yarnold PR; Scheetz MH; Pi J; Pennick G; Mehta J
    Antimicrob Agents Chemother; 2009 May; 53(5):1793-6. PubMed ID: 19223632
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Therapeutic Drug Monitoring of Voriconazole in Critically Ill Pediatric Patients: A Single-Center Retrospective Study.
    Taher KW; Almofada R; Alomair S; Albassam AA; Alsultan A
    Paediatr Drugs; 2024 Mar; 26(2):197-203. PubMed ID: 38228969
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Pharmacokinetic interaction between voriconazole and methadone at steady state in patients on methadone therapy.
    Liu P; Foster G; Labadie R; Somoza E; Sharma A
    Antimicrob Agents Chemother; 2007 Jan; 51(1):110-8. PubMed ID: 17074798
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Voriconazole pharmacokinetics following HSCT: results from the BMT CTN 0101 trial.
    Hope WW; Walsh TJ; Goodwin J; Peloquin CA; Howard A; Kurtzberg J; Mendizabal A; Confer DL; Bulitta J; Baden LR; Neely MN; Wingard JR;
    J Antimicrob Chemother; 2016 Aug; 71(8):2234-40. PubMed ID: 27121401
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The role of candidate genetic polymorphisms in the interaction between voriconazole and cyclosporine in patients undergoing allogeneic hematopoietic cell transplantation: An explorative study.
    Zgheib NK; Alameddine R; Massoud R; Nasr R; Zahreddine A; El Cheikh J; Mahfouz R; Bazarbachi A
    Curr Res Transl Med; 2020 Apr; 68(2):51-58. PubMed ID: 32094096
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Population pharmacokinetics of ciclosporin in haematopoietic allogeneic stem cell transplantation with emphasis on limited sampling strategy.
    Wilhelm AJ; de Graaf P; Veldkamp AI; Janssen JJ; Huijgens PC; Swart EL
    Br J Clin Pharmacol; 2012 Apr; 73(4):553-63. PubMed ID: 21988410
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Role of letermovir for prevention of cytomegalovirus infection after allogeneic haematopoietic stem cell transplantation.
    Razonable RR
    Curr Opin Infect Dis; 2018 Aug; 31(4):286-291. PubMed ID: 29746444
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Variable magnitude of drug interaction between oral voriconazole and cyclosporine A in recipients of allogeneic hematopoietic stem cell transplantation.
    Kikuchi T; Mori T; Yamane A; Kato J; Kohashi S; Okamoto S
    Clin Transplant; 2012; 26(5):E544-8. PubMed ID: 23061764
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Population pharmacokinetics, safety and dosing optimization of voriconazole in patients with liver dysfunction: A prospective observational study.
    Tang D; Yan M; Song BL; Zhao YC; Xiao YW; Wang F; Liang W; Zhang BK; Chen XJ; Zou JJ; Tian Y; Wang WL; Jiang YF; Gong GZ; Zhang M; Xiang DX
    Br J Clin Pharmacol; 2021 Apr; 87(4):1890-1902. PubMed ID: 33010043
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Letermovir Prophylaxis Decreases Burden of Cytomegalovirus (CMV) in Patients at High Risk for CMV Disease Following Hematopoietic Cell Transplant.
    Johnsrud JJ; Nguyen IT; Domingo W; Narasimhan B; Efron B; Brown JW
    Biol Blood Marrow Transplant; 2020 Oct; 26(10):1963-1970. PubMed ID: 32653623
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Effects of Voriconazole Exposure on the Pharmacokinetics of Tacrolimus in Lung Transplantation Patients, Based on Therapeutic Drug Monitoring Data.
    Chen W; Wang X; Li B; Qin W; Li S; Wang X; Chen W; Zhang X; Li P; Zuo X
    J Clin Pharmacol; 2022 Oct; 62(10):1310-1320. PubMed ID: 35485761
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.